Butonitazene
A synthetic opioid analgesic
| Butonitazene | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Butonitazene is a synthetic opioid analgesic that belongs to the benzimidazole family of compounds. It is structurally related to other opioids such as etazene and metonitazene. Butonitazene is known for its potent analgesic effects, which are mediated through its action as an agonist at the mu-opioid receptor.
Chemical structure and properties
Butonitazene is characterized by its complex chemical structure, which includes a benzimidazole core. The chemical formula of Butonitazene is C23H30N2O2. The presence of the diethylaminoethyl group and the phenylpiperidine moiety are significant for its pharmacological activity.
Pharmacology
Butonitazene acts primarily as a mu-opioid receptor agonist. This receptor is part of the opioid receptor family, which also includes the delta-opioid receptor and the kappa-opioid receptor. Activation of the mu-opioid receptor by Butonitazene leads to analgesia, euphoria, and respiratory depression, which are common effects associated with opioid use.
Medical use
Butonitazene has been investigated for its potential use as an analgesic in clinical settings. However, due to its potency and the risk of adverse effects such as respiratory depression, its use is limited and it is not widely available for medical use.
Adverse effects
The adverse effects of Butonitazene are similar to those of other opioids. These include:
- Respiratory depression
- Sedation
- Nausea and vomiting
- Constipation
- Risk of dependence and addiction
Legal status
Due to its potential for abuse and addiction, Butonitazene is classified as a controlled substance in many countries. Its legal status varies, and it is important to consult local regulations regarding its use and distribution.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD